Clinical trial
Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer
NCT04348643
Study timeline
Study start (estimated)2020-02-20Date precision: day
Registry last updated2026-07-10
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Solid Tumorunresolved
Lung Cancerunresolved
Colorectal Cancerunresolved
Liver Cancerunresolved
Pancreatic Cancerunresolved
Gastric Cancerunresolved
Breast Cancerunresolved
Interventions
CEA CAR-T cellsBIOLOGICAL
Sponsors & collaborators
Chongqing Precision Biotech Co., Ltdlead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04348643 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.